A case of neonatal thrombocytopenia caused by maternal alloimmunization against a new platelet antigen (Bzh<sup>a</sup>, HPA‐34bw) located on GPIIIa

Bertrand, Gérald; Danger, Yannic; Laurichesse, Mathieu; Vérité, Franck; Renac, Virginie

doi:10.1111/trf.15120

Cited by 2 publications

(1 citation statement)

References 5 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The human platelet antigens (HPAs) are formed due to genetic allovariants of glycoproteins on the platelet surfacethese glycoproteins are often crucial for platelet function by being receptors for extracellular matrix proteins and coagulation factors. To date, there are a total of 42 HPA antigens designated in 35 systems (HPA-1 to -35) that may cause alloimmune complications [6][7][8][9][10][11][12][13]. A link to an updated database with antigen and population frequency data is expected to be available at the ISBT Platelet Immunology Working Party homepage during 2019.…”

Section: Alloantigenic Targets On Plateletsmentioning

confidence: 99%

Serological and molecular typing in platelet alloantibody investigations

Ahlén

2019

ISBT Science Series

View full text Add to dashboard Cite

Alloimmunization against platelet antigens causes complications in transfusion settings as platelet transfusion refractoriness and post-transfusion purpura, as well as in pregnancy, causing fetal/neonatal alloimmune thrombocytopenia. Strategies for the laboratory investigations depend on a repertoire of serological and molecular assays and are often dependent on timing and objective. Technical improvements have led to a number of sophisticated methods for alloantigen typing and alloantibody identifications during the last decade; however, some traditional methods are still beneficial. The laboratory investigations should ensure that the causative antibody specificities are identified as soon as possible to support the correct diagnosis and guide the selection of compatible platelets if needed.

show abstract

Section: Alloantigenic Targets On Plateletsmentioning

confidence: 99%

Serological and molecular typing in platelet alloantibody investigations

Ahlén

2019

ISBT Science Series

View full text Add to dashboard Cite

show abstract

High-Throughput Screening of Blood Donors for Twelve Human Platelet Antigen Systems Using Next-Generation Sequencing Reveals Detection of Rare Polymorphisms and Two Novel Protein-Changing Variants

Vorholt

Hamker

Sparka

et al. 2020

Transfus Med Hemother

View full text Add to dashboard Cite

Background: Exposure to non-matching human platelet alloantigens (HPA) may result in alloimmunization. Antibodies to HPA can be responsible for post-transfusion purpura, refractoriness to donor platelets, and fetal and neonatal alloimmune thrombocytopenia. For the supply of compatible apheresis platelet concentrates, the HPA genotypes are determined in a routine manner. Methods: Here, we describe a novel method for genotyping twelve different HPA systems simultaneously, including HPA-1 to HPA-5, HPA-9w, HPA-10w, HPA-16w, HPA-19w, HPA-27w, and the novel HPA-34w by means of amplicon-based next-generation sequencing (NGS). Blood donor samples of 757 individuals with a migration background and 547 of Western European ancestry were genotyped in a mass-screening setup. An in-house software was developed for fast and automatic analysis. TaqMan assay and Sanger sequencing results served for validation of the NGS workflow. Finally, blood donors were divided in several groups based on their country of origin and the allele frequencies were compared. Results: For 1,299 of 1,304 samples (99.6%) NGS was successfully performed. The concordance with TaqMan assay and Sanger sequencing results was 99.8%. Allele-calling dropouts that were observed for two samples with the TaqMan assay caused by rare single nucleotide polymorphisms were resolved by NGS. Additionally, twenty rare and two novel variants in the coding regions of the genes ITGB3, GPB1A, ITGBA2, and CD109 were detected. The determined allele frequencies were similar to those published in the gnomAD database. Conclusions: No significant differences were observed in the distribution of allele frequencies of HPA-1 through HPA-5 and HPA-15 throughout the analyzed groups except for a lower allele frequency for the HPA-1b allele in the group of donors with Southern Asian ancestry. In contrast, other nucleotide variants that have not yet been phenotypically characterized occurred three times more often in blood donors with a migration background. High-throughput amplicon-based NGS is a reliable method for screening HPA genotypes in a large sample cohort simultaneously. It is easily upgradeable for genotyping additional targets without changing the setup or the analysis pipeline. Mass-screening methods will help building up blood donor registries to provide matched blood products.

show abstract

A case of neonatal thrombocytopenia caused by maternal alloimmunization against a new platelet antigen (Bzh^a, HPA‐34bw) located on GPIIIa

Cited by 2 publications

References 5 publications

Serological and molecular typing in platelet alloantibody investigations

Serological and molecular typing in platelet alloantibody investigations

High-Throughput Screening of Blood Donors for Twelve Human Platelet Antigen Systems Using Next-Generation Sequencing Reveals Detection of Rare Polymorphisms and Two Novel Protein-Changing Variants

Contact Info

Product

Resources

About

A case of neonatal thrombocytopenia caused by maternal alloimmunization against a new platelet antigen (Bzha, HPA‐34bw) located on GPIIIa

Cited by 2 publications

References 5 publications

Serological and molecular typing in platelet alloantibody investigations

Serological and molecular typing in platelet alloantibody investigations

High-Throughput Screening of Blood Donors for Twelve Human Platelet Antigen Systems Using Next-Generation Sequencing Reveals Detection of Rare Polymorphisms and Two Novel Protein-Changing Variants

Contact Info

Product

Resources

About

A case of neonatal thrombocytopenia caused by maternal alloimmunization against a new platelet antigen (Bzh^a, HPA‐34bw) located on GPIIIa